2 ‘Strong Buy’ Stocks That Wall Street Believes Can Soar 360% to 780%

Group 1: Company Overview - Eledon Pharmaceuticals (ELDN) is a clinical-stage biotech company focused on immunology, particularly in immunomodulation for transplantation and some work in autoimmune and neurodegenerative diseases [2] - Eledon was included in the Russell 3000 and Russell 2000 indices in June, increasing its visibility as it approaches multiple clinical catalysts [2] Group 2: Financial Performance - Eledon is currently valued at $154.5 million, with its stock having dipped 37% year-to-date but surged 114% over the last two years [3] - As of Q2, Eledon ended with $107.6 million in cash, cash equivalents, and short-term investments, which is expected to fund operations through the end of 2026 [5] Group 3: Product Development - Eledon's lead asset, tegoprubart, is an investigational anti-CD40L antibody aimed at preventing organ transplant rejection and curing autoimmune illnesses by regulating the CD40-CD40L immunological pathway [4] - Positive findings from ongoing trials of tegoprubart were presented at the World Transplant Congress in August 2025, showing no reports of mortality, graft loss, or drug-related complications among trial participants [5] - The company plans to present topline results of its Phase 2 BESTOW kidney transplantation study in November, which could establish tegoprubart as a cornerstone in transplant immunosuppression if successful [6] Group 4: Market Potential - Tegoprubart holds significant therapeutic potential in solid organ transplantation, cell transplantation, xenotransplantation, and autoimmune illnesses such as amyotrophic lateral sclerosis (ALS) [7]